Oxidative status and malondialdehyde in beta-thalassaemia patients.
about
Oxidative stress and age-related changes in T cells: is thalassemia a model of accelerated immune system aging?Ineffective erythropoiesis in β -thalassemiaOxidative stress and the homeodynamics of iron metabolismBone disease in thalassemia: a frequent and still unresolved problem.Association of Iron Overload with Oxidative Stress, Hepatic Damage and Dyslipidemia in Transfusion-Dependent β-Thalassemia/HbE Patients.Iron elevation and adipose tissue remodeling in the epididymal depot of a mouse model of polygenic obesity.Novel approach to reactive oxygen species in nontransfusion-dependent thalassemiaBiological and histopathological investigations of moclobemide on injured ovarian tissue following induction of ischemia-reperfusion in rats.The Preventive Effect of Dexmedetomidine Against Postoperative Intra-abdominal Adhesions in RatsRespiratory Burst Enzymes, Pro-Oxidants and Antioxidants Status in Bangladeshi Population with β-Thalassemia Major.Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.Iron requirements based upon iron absorption tests are poorly predicted by haematological indices in patients with inactive inflammatory bowel diseasePremature atherosclerosis in children with beta-thalassemia major: New diagnostic marker.Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.Molecular therapies in beta-thalassaemia.Oxidative stress and antioxidant status in beta-thalassemia heterozygotes.Iron overload: consequences, assessment, and monitoring.Current approach to iron chelation in children.Thalassaemia and risk of cancer: a population-based cohort study.The effects of enoxaparin on the liver in experimental pneumoperitoneum model.Soluble hemojuvelin in transfused and untransfused thalassaemic subjects.Fibroblast involvement in soft connective tissue calcificationLack of correlation between non-labile iron parameters, total carbonyl and malondialdehyde in major thalassemia.The effect of iron(III) on the activity of selenoenzymes and oxidative damage in the liver of rats. Interaction with natural antioxidants and deferiprone.An investigation about the inhibition of acute ischemia/reperfusion damage by dexmedetomidine in rat ovarian tissue.Oxidative status and plasma lipid profile in β-thalassemia patients.The influence of gemfibrozil on malondialdehyde level and paraoxonase 1 activity in wistar and fisher rats.Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15.Hypoxia biomarkers, oxidative stress, and circulating microparticles in pediatric patients with thalassemia in Upper Egypt.Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity.Effect of antioxidant therapy on hepatic fibrosis and liver iron concentrations in β-thalassemia major patients.Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major.Increased iron levels and lipid peroxidation in a Mediterranean population of Spain.Serum Paraoxonase Activity and Malondialdehyde Serum Concentrations Remain Unaffected in Response to Hydroxyurea Therapy in β-Thalassemia Patients.Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spectroscopy.A comparative investigation of biochemical and histopathological effects of thiamine and thiamine pyrophosphate on ischemia-reperfusion induced oxidative damage in rat ovarian tissue.Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.Oxidation status of β-thalassemia minor and Hb H disease, and its association with glycerol lysis time (GLT50).Quantitative determination of ortho- and meta-tyrosine as biomarkers of protein oxidative damage in beta-thalassemia.Nonionic surfactant based thymoquinone loaded nanoproniosomal formulation: in vitro physicochemical evaluation and in vivo hepatoprotective efficacy.
P2860
Q26752041-21B675E0-B51D-427C-9E29-F64AD3E4F542Q26830255-34801FB2-131E-40F1-84D1-2448144DEC86Q28082925-189C15FA-C08D-4854-85EC-48AED41041DDQ33337925-D375913C-C319-4D10-B76F-A29A634E6E9DQ33774553-2E7404B2-3925-406C-992A-9BDA5E6D9ABCQ33835014-8452E8C6-F85C-4E7C-BE55-1ECF318D61A7Q33993973-96BE022B-947A-46EF-B611-55C977968A12Q34661741-5EDE12D5-AEF5-4617-840F-FA78BF7F5DF6Q34993253-6ED1E8DC-0755-4923-81DD-2058D8685E1DQ35809497-9A128660-DFEF-484C-BA48-3DD26494689BQ35919222-E40CC144-9738-4C65-924A-CA1178D7D297Q36043365-3EEA2D2D-CE10-4C2C-87A5-44E028E58E94Q36303189-5D64A9C9-CC8B-428A-A61D-04A337D342B2Q36343351-D349CE88-16E4-4F34-BEE0-62E905EEF80AQ36665342-988302F1-B637-4F6F-BA49-95D0FE50B638Q37528614-EA45C4BC-0ECB-4F7D-9782-E2399667DF0EQ37650453-76280CB6-35CA-410B-B3AD-A141EF21AFCEQ38197269-4B8CB5FB-D1DF-449C-8C26-EF96B5B09745Q38448353-26A07483-6EE2-4400-9DFB-286C7AC52CD3Q39095549-C4086356-AAE6-41DD-A399-9E09C4F51AE0Q40605803-A9AD7456-3B9A-4E16-A955-CDF74DE2FA7EQ41596248-7ED65632-AFAC-4410-8B08-1B8A72515B51Q42999299-50D5B58B-4142-45C3-9F4A-525F9E37462BQ43044183-0BAA3152-0F8B-4E49-855B-9BEC47FA8507Q44148022-BD986566-AE4E-4410-BC04-6BAA48C5A778Q44478196-AF424738-67C2-439D-8DEF-48D38AB4B9CCQ45038067-AF234609-FD49-4028-8F6E-B8EFB14FD66FQ45883725-078B75C4-39A0-4AA5-89FD-A1EFAFDC8AF4Q45901373-1A2644D9-9431-4486-8C9B-D5DD8BDAE207Q46254751-570AE949-698B-4F30-926C-9A6499FE20F9Q46364415-408BB684-B363-4E3E-8941-D61D30A912B2Q46460675-76C700AA-AF77-4D84-A05D-434ADD822400Q46576277-E3E555FC-2DBB-45C0-92B9-C693BA0C05E3Q46633489-6CCB1FBA-18FD-411C-B0CB-2E23E1345700Q46712890-ACD11E6D-0453-4464-B91C-280B4C923707Q46805233-CD79598E-710C-44F2-B7A2-18985DEAB791Q46906583-44336C8C-053C-455E-9E7B-12F1AD008637Q46921822-65DC8765-0F21-4691-AB24-373E80C19072Q46959226-5D58B3A8-47BE-4DA6-8274-80E8B459CBB5Q48285216-1BAF5FA6-AA01-44C5-90EB-C40DF8C3F59C
P2860
Oxidative status and malondialdehyde in beta-thalassaemia patients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Oxidative status and malondialdehyde in beta-thalassaemia patients.
@en
Oxidative status and malondialdehyde in beta-thalassaemia patients.
@nl
type
label
Oxidative status and malondialdehyde in beta-thalassaemia patients.
@en
Oxidative status and malondialdehyde in beta-thalassaemia patients.
@nl
prefLabel
Oxidative status and malondialdehyde in beta-thalassaemia patients.
@en
Oxidative status and malondialdehyde in beta-thalassaemia patients.
@nl
P2093
P2860
P1476
Oxidative status and malondialdehyde in beta-thalassaemia patients.
@en
P2093
G Fiorelli
Giuliana Cighetti
M D Cappellini
P2860
P356
10.1046/J.1365-2362.2002.0320S1055.X
P478
32 Suppl 1
P577
2002-03-01T00:00:00Z